Avellino Labs

Avellino Labs is a genetic testing service provider and a global leader in gene therapy and molecular diagnostics, specializing in genetic diagnostics, data, and therapeutic research and development. Similar genetic tests enable patients to detect diseases earlier, providing better treatment options and overall improved care. The company is committed to creating new opportunities for early disease detection, starting with ophthalmic genetic disorders. Headquartered in Silicon Valley, California, Avellino Labs operates in South Korea, Japan, China, and the UK, offering more personalized healthcare services to people worldwide. The company launched the world's first DNA test confirming the presence of genetic markers associated with corneal diseases, providing life-changing critical information for patient treatment decisions and follow-up care. It also pioneered the use of CRISPR gene-editing technology to manage and cure underlying conditions such as lattice corneal dystrophy, granular corneal dystrophy, and Reis-Bucklers corneal dystrophy.